Martina Rauscher
Zurich, ZH, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Characterization of vaccine viremia, attenuation reversion, and safety: Combined results from the TAK-003 dengue vaccine clinical development program.
Journal: Vaccine
Published: December 19, 2025
Letter to Editor: Rattanaumpawan et al. Severe dengue hemorrhagic fever after TAK-003 dengue vaccination: A case report of a potential vaccine-associated adverse reaction.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: December 12, 2025
Comment on: Pettersson et al. Qdenga-induced dengue caused by minor DENV-2 subvariant(s) in the vaccine, with two amino acid substitutions in the E protein.
Journal: Journal of travel medicine
Published: December 05, 2025
Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine.
Journal: Expert review of vaccines
Published: March 18, 2025
Immunogenicity, Safety, and Efficacy of a Tetravalent Dengue Vaccine in Children and Adolescents: An Analysis by Age Group.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: March 12, 2024
Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination.
Journal: The Journal of infectious diseases
Published: June 01, 2023
Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial.
Journal: The Lancet. Global health
Published: February 22, 2023
Safety of Dengue Vaccine?
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 05, 2022
Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study.
Journal: PLoS neglected tropical diseases
Published: June 24, 2022
Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: January 18, 2022
Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adults.
Journal: Vaccine
Published: December 01, 2021
Last Updated: 09/26/2026